ClinicalTrials.gg
Not yet recruitingNCT07479836OPTIVOUpdated Mar 18, 2026

Optimizing Ventilation to Improve Survival From Out-of-hospital Cardiac Arrest: the OPTIVO Randomized Controlled Trial

An interventional study of Low Volume Ventilation and High Volume Ventilation in Cardiac Arrest, sponsored by Sunnybrook Health Sciences Centre. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.

Primary conditionOut-of-Hospital Cardiac ArrestRegistry: Heart ArrestReclassifiedWhy we changed it
Registry
Heart Arrest — the first condition term the registry derived for this study.
ClinicalTrials.gg
Out-of-Hospital Cardiac Arrest
Why
  1. The study's title name Out-of-Hospital Cardiac Arrest, a narrower term within Heart Arrest.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sunnybrook Health Sciences Centre · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,656
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Out-of-Hospital Cardiac Arrest with a site in Canada — 4 open to participants now, 6 under way, none of them phase 3. Out-of-Hospital Cardiac Arrest · Canada.

Planned enrollment
2nd of 14
1,656 · median 397
Started
2026
the only one that year
No phase
12 of 16
3 open now
Registered
15th of 16
by date
Lead sponsor
5 of 16
Sunnybrook Health Sciences Centre

Among the 16 studies in Out-of-Hospital Cardiac Arrest with a site in Canada, this one is the 2nd largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2026, is one of 12 with no phase, and was the 15th registered.

Out-of-Hospital Cardiac Arrest

314 studies on the registry are indexed under Out-of-Hospital Cardiac Arrest; 93 are open to participants now.

Browse Out-of-Hospital Cardiac Arrest studies →

Open to participants now

4 of the 16 studies in Out-of-Hospital Cardiac Arrest with a site in Canada are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 66 Out-of-Hospital Cardiac Arrest studies recruiting now, 46 (70%) set no upper age limit and 13 (20%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Out-of-Hospital Cardiac Arrest with a site in Canada, or all of them as a file.
02

Study summary

When the heart stops pumping during cardiac arrest, cardiopulmonary resuscitation (CPR) is used to continue pushing blood and providing oxygen to vital organs. CPR involves a combination of chest compressions (to push the blood) and ventilations (to provide oxygen and gas exchange). There is a lot of research that has helped to optimize the provision of chest compressions, however there is considerably less research available to guide ventilations. The current guideline recommendations are based on limited data, and no data that is specific to cardiac arrest patients. There is a recognized need for research to better guide ventilation during CPR. This research will help to better define appropriate ventilation targets for cardiac arrest patients.

Read the detailed description

Rationale Chest compressions and ventilations are the two primary components of cardiopulmonary resuscitation (CPR); one of the few treatments to get a Class 1 recommendation from the American Heart Association (AHA) guidelines for the treatment of patients in cardiac arrest. While there is a significant body of literature examining chest compression quality the evidence regarding optimal ventilation quality is limited.

Current guidelines recommend providing ventilations of 500-600ml, or enough for chest rise, to adult patients in cardiac arrest in either a 30:2 ventilation to chest compression ratio without an advanced airway or one breath every six seconds (10 per minute) with an advanced airway. Little has changed in these recommendations over the last 10 years. It is recognized, however, that the evidence informing these recommendations is based on limited, low-quality evidence from non-cardiac arrest populations. Both the International Liaison Committee on Resuscitation (ILCOR) and the AHA have identified that there remains a significant knowledge gap with respect to optimal ventilation strategies during out-of-hospital cardiac arrest (OHCA) resuscitation.

Hyperventilation and Hypoventilation Proper ventilation during cardiac arrest is important to provide oxygenation to vital organs, such as the brain, and remove harmful metabolism by-products (e.g. carbon dioxide). Improper ventilation, both hypoventilation (too little) and hyperventilation (too much) can be detrimental to patient survival and neurological outcomes. What constitutes optimal ventilation, however, is unknown.

Hypoventilation can lead to increased ischemic injury from reduced oxygen delivery to the brain during cardiac arrest. It can also cause a build-up of CO2 resulting in a respiratory acidosis which can have detrimental consequences to the heart and cardiovascular function. The amount of ventilation that is required during cardiac arrest though is not known. Research examining passive oxygenation (no active ventilation) demonstrates mixed results with respect to cardiac arrest outcomes. While outcomes have been mixed, in general passive oxygenation may not provide sufficient tidal volumes (often under 20mL) generated with chest compressions for adequate gas exchange.

Hyperventilation can lead to air-trapping and an increase in intrathoracic pressure, leading to increased right atrial pressure, decreased coronary perfusion pressure, and decreased venous return and cardiac output.9 During positive pressure ventilation, the increase in intrathoracic pressure during inspiration leads to a decrease in right ventricular preload, ultimately decreasing cardiac output. Decreased cardiac output and coronary perfusion lead to reduced rates of return of spontaneous circulation, which ultimately leads to reduced survival. Aggressive ventilations can also cause gastric insufflation and gastric regurgitation leading to pneumonia and other associated airway complications. Previous research has shown that ventilation with lower volumes (365mL) is associated with lower airway pressures, and reduced incidence of gastric insufflation without changes in oxygen saturation. Similarly, ventilations with 6mL/kg result in same CO2 clearance as larger tidal volumes. Furthermore, research examining end-tidal CO2 tracings has hypothesized that hyperinflation is a common phenomenon during cardiac arrest.

Performance of Ventilation During Cardiac Arrest

Proper ventilations during cardiac resuscitation are challenging to perform. Chang et al. (2019) found that lung inflation occurred infrequently during pauses in chest compressions, however, that an increased number of ventilations were associated with increased rates of ROSC and survival to hospital discharge. Vissers et al. (2019) found no correlation between ventilation rate and ROSC, however found that hyperventilation was common, occurring in 85% of resuscitations. Variability in patient characteristics and logistical challenges, such as limited physical space, make it difficult to perform consistent high-quality ventilations.

While AHA guideline indicate 500 to 600mL of volume per ventilation, recognition of chest rise often occurs at volumes that are significantly lower. This creates a conflict within the AHA recommendation on the appropriate volume of ventilation. Chest rise has been shown to occur at volumes 362 to 402mL with an average of 384mL.

Previous Literature

There is a paucity of high-quality evidence to support current ventilation guideline recommendations, and the available evidence lacks patient-oriented outcomes such as survival to hospital discharge, or neurological outcome. Evidence for ventilations during cardiac arrest is mostly borrowed from animal research or anesthesiology literature indicating that ventilations of 6 to 8 ml/kg of ideal body weight is sufficient in patients in respiratory arrest and is enough volume to create visible chest rise. This volume has not been demonstrated to be sufficient, nor ideal in the cardiac arrest population. It is known that cardiac output is approximately 30% of normal during chest compressions and therefore ventilation requirements may also be different.

Previous research has found that passive insufflation is as effective as positive pressure ventilation, at least during the first few minutes of witnessed cardiac arrest resuscitation which begs the question of how much ventilation is required. Other research examining ventilation quality has found decreased survival associated with hyperventilation. A small observational study by Sutton et al. (2019) found a decrease in survival and neurological outcome in paediatric patients with both low and high ventilation rates. They also identified that the 'sweet spot' for ventilation rate, that was associated with the highest survival and neurological outcome, was higher than recommended by the AHA guidelines.

One significant barrier to optimizing ventilations during OHCA has been the inability to accurately measure the quality of ventilations being performed by paramedics in the field. Until recently there has been no method available in the prehospital setting to provide accurate, real-time measurement and feedback of ventilation rate and/or volume. Utilization of feedback devices has been shown to improve the quality of chest compressions performed in the field. Similarly the use of tidal volume feedback devices has been shown to improve the proportion of ventilations within target range during simulated cardiac arrest resuscitation. A simulation study using the ZOLL Accuvent® ventilation monitor found that ventilations significantly improved with the use of real-time feedback during simulated cardiac arrests. The authors found that the use of real-time feedback resulted in a increase in target compliance for ventilation rate from 41% to 71%, ventilation volume from 31% to 79% and for rate and volume together from 10% to 63%. Similarly, Lyngby et al. (2021) performed a randomized controlled trial with 64 paramedics using simulated cardiac arrest scenarios. They found that use of real-time feedback was able to significantly improve guideline compliance in terms of ventilation rate and volume as combined or individual parameters. Charlton et al. (2021) found similar results in 106 paramedics when performing 2-minute simulated scenarios.

Our previous publication is the only published literature examining ventilation during cardiac arrest with ventilation feedback devices. We identified that without feedback, ventilations rarely meet guideline recommendations, however compliance significantly improved with ventilation feedback. The average ventilation volume was much lower than guideline targets (395mL).

Significance of the project

This study will constitute the most rigorous evaluation of the impact of ventilations during cardiac arrest on patient outcomes. This is an area of research that is of huge importance but is significantly under studied as until recently it was not possible to reliably measure ventilation quality in the field. There are significant knowledge gaps in our understanding of the importance of ventilations during resuscitation and what are the key indicators of ventilation quality. Multiple simulation studies have indicated that use of real-time feedback significantly improves the quality of ventilations performed by paramedics, however none of these studies were on real patients, performed in the field, or had any patient-oriented outcomes associated with them.

This study will build upon previous simulation studies to examine real-time feedback in the field during actual cardiac arrests and examine the association of ventilations with patient outcomes. The results of this study will have guideline informing implications, leading to improvements in clinical practice. These improvements in care could lead to increased survival from out-of-hospital cardiac arrest. Further, this research will lead to other important questions regarding the relationship between ventilations, cardiac arrest care, prognostication and patient outcomes.

03

Conditions studied

  • Cardiac Arrest

Browse trials for

Keywords

  • Resuscitation
  • Ventilation
  • Cardiopulmonary Resuscitation
  • Out-of-Hospital Cardiac Arrest
04

In context

Out-of-Hospital Cardiac Arrest Reclassified

314 studies on the registry are indexed under Out-of-Hospital Cardiac Arrest; 93 are open to participants now.

This study's planned enrollment of 1,656 is above the median of 218 across 179 interventional studies indexed under Out-of-Hospital Cardiac Arrest.

Browse Out-of-Hospital Cardiac Arrest studies →

Lead sponsor

Sunnybrook Health Sciences Centre is the lead sponsor of 585 studies on the registry; 135 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Compared within Out-of-Hospital Cardiac Arrest, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Arrest. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (>=18 years of age)
  • presumed cardiac etiology
  • treated by paramedics
  • Ventilation monitor utilized

Exclusion criteria

Exclusion Criteria:

  • Do Not Resuscitate (DNR) order
  • No use of ventilation monitor
  • Traumatic cardiac arrest
  • Pregnant patients
  • Prisoners
  • Respiratory cause of cardiac arrest (e.g. drowning, hanging, suffocation, opioid-related)
06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
1,656 participants (estimated)

Study arms

  • Experimental
    Low Volume (350ml (+/50ml)

    Other: Low Volume Ventilation

  • Active comparator
    600ml (+/-50ml)

    Other: High Volume Ventilation

Interventions

  • OtherLow Volume Ventilation

    Patients in cardiac arrest will be ventilated with a volume of 350ml (+/- 50 ml)

  • OtherHigh Volume Ventilation

    600ml (+/-50ml)

07

What researchers measure

Primary outcomes

  1. Return of Spontaneous Circulation

    At any time in the prehospital setting as documented by paramedics

    Time frame: Prior to arrival at the hospital. This will occur within 1 hr after enrolment in most patients.

Secondary outcomes

  1. Survival to Hospital Discharge

    Survival at hospital discharge

    Time frame: Discharge from hospital is likely to occur within 30 days of the cardiac arrest event for most patients.

  2. Survival to Hospital Admission

    Survival to hospital admission obtained through administrative datasets

    Time frame: Hospital Admission - estimated to occur within 6 hrs of arrival at hospital for most patients.

08

Study locations

1 site
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Jan 2028, 22 months later.

Of 93 non-industry interventional studies with no phase under Out-of-Hospital Cardiac Arrest, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 57. This study's planned 22 months is below that.

Counting every sponsor, half of 95 studies reached it within 34 months; a quarter within 19 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Mar 18, 2026
StartEst.
Mar 2026
Primary completionEst.
Jan 2028
CompletionEst.
Mar 2028
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07479836
Responsible party
Ian Drennan (Affiliate Scientist, Sunnybrook Health Sciences Centre) — Principal investigator
First posted
Mar 18, 2026
Start date
Mar 2026 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Mar 18, 2026

Study contacts

Ian Drennan, PhD
Contact
ian.drennan@sunnybrook.ca
416-667-2200 ext. 0
Ian Drennan, PhD
principal investigator · Sunnybrook Health Sciences Centre
Sheldon Cheskes, MD
principal investigator · Sunnybrook Health Sciences Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion